These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33134030)

  • 1. Bile Duct Injury due to Drug Induced Liver Injury.
    Grewal P; Ahmad J
    Curr Hepatol Rep; 2019; 18(3):269-273. PubMed ID: 33134030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerosing Cholangitis-Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury.
    Ahmad J; Rossi S; Rodgers SK; Ghabril M; Fontana RJ; Stolz A; Hayashi PH; Barnhart H; Kleiner DE; Bjornsson ES
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):789-790. PubMed ID: 29966706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiosyncratic drug-induced liver injury: an overview.
    Hussaini SH; Farrington EA
    Expert Opin Drug Saf; 2007 Nov; 6(6):673-84. PubMed ID: 17967156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition.
    Beaudoin JJ; Yang K; Adiwidjaja J; Taneja G; Watkins PB; Siler SQ; Howell BA; Woodhead JL
    Front Pharmacol; 2022; 13():1085621. PubMed ID: 36733378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.
    Molleston JP; Fontana RJ; Lopez MJ; Kleiner DE; Gu J; Chalasani N;
    J Pediatr Gastroenterol Nutr; 2011 Aug; 53(2):182-9. PubMed ID: 21788760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab-Induced Vanishing Bile Duct Syndrome.
    Eiswerth MJ; Heckroth MA; Ismail A; Gondim DD; Kaufman R
    Cureus; 2022 Feb; 14(2):e21940. PubMed ID: 35273881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and pathological features in 138 cases of drug-induced liver injury].
    Lai RT; Wang H; Gui HL; Ye MZ; Dai WJ; Xiang XG; Zhao GD; Wang WJ; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):185-9. PubMed ID: 22475136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center.
    Ettel M; Gonzalez GA; Gera S; Eze O; Sigal S; Park JS; Xu R
    Hum Pathol; 2017 Oct; 68():92-98. PubMed ID: 28873351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary sclerosing cholangitis in patients with drug-induced liver injury.
    Gudnason HO; Björnsson HK; Gardarsdottir M; Thorisson HM; Olafsson S; Bergmann OM; Björnsson ES
    Dig Liver Dis; 2015 Jun; 47(6):502-7. PubMed ID: 25840876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use.
    Yang K; Moga T; Nallapeta NS; Duve R; Miranda CJ; Ismail M; Mahl T
    Cureus; 2022 Dec; 14(12):e32262. PubMed ID: 36620795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term sequelae of drug-induced liver injury.
    Björnsson ES; Andrade RJ
    J Hepatol; 2022 Feb; 76(2):435-445. PubMed ID: 34688732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced liver injury.
    Leise MD; Poterucha JJ; Talwalkar JA
    Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
    Greca RD; Cunha-Silva M; Costa LBE; Costa JGF; Mazo DFC; Sevá-Pereira T; Nascimento MMC; Pereira IE; Oliveira FC; Faria GAS; Neto FLP; Almeida JRS
    Ann Hepatol; 2020; 19(1):107-112. PubMed ID: 31537508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.
    Kleiner DE; Chalasani NP; Lee WM; Fontana RJ; Bonkovsky HL; Watkins PB; Hayashi PH; Davern TJ; Navarro V; Reddy R; Talwalkar JA; Stolz A; Gu J; Barnhart H; Hoofnagle JH;
    Hepatology; 2014 Feb; 59(2):661-70. PubMed ID: 24037963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of liver biopsy in the diagnosis of drug-induced liver injury.
    Ahmad J; Barnhart HX; Bonacini M; Ghabril M; Hayashi PH; Odin JA; Rockey DC; Rossi S; Serrano J; Tillmann HL; Kleiner DE;
    J Hepatol; 2022 May; 76(5):1070-1078. PubMed ID: 35074471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proposed pathologic sub-classification of drug-induced liver injury.
    Wang T; Zhao X; Shao C; Ye L; Guo J; Peng N; Zhang H; Li J; Kong Y; You H; Jia J
    Hepatol Int; 2019 May; 13(3):339-351. PubMed ID: 30977034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis.
    Yang J; Yu YL; Jin Y; Zhang Y; Zheng CQ
    World J Gastroenterol; 2016 Sep; 22(33):7579-86. PubMed ID: 27672278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug induced liver injury with analysis of alternative causes as confounding variables.
    Teschke R; Danan G
    Br J Clin Pharmacol; 2018 Jul; 84(7):1467-1477. PubMed ID: 29607530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic features of drug-induced vanishing bile duct syndrome].
    Ye LH; Wang CK; Zhang HC; Liu ZQ; Zheng HW
    Zhonghua Gan Zang Bing Za Zhi; 2017 Apr; 25(4):317-320. PubMed ID: 28494557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
    Palmer M; Regev A; Lindor K; Avigan MI; Dimick-Santos L; Treem W; Marcinak JF; Lewis JH; Anania FA; Seekins D; Shneider BL; Chalasani N
    Aliment Pharmacol Ther; 2020 Jan; 51(1):90-109. PubMed ID: 31762074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.